Drug Development

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.

Two years after a landmark rejection, the bid to approve MDMA-assisted therapy for PTSD is back. This is more than a resubmission; it's a test case for a new paradigm in medicine.

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

Grifols completes its landmark SPARTA trial for a rare lung disease, offering new hope to patients and signaling a major strategic move in the biotech market.

Partner Ocumension submits NCX 470 for approval, a move poised to tap into a massive patient market and validate Nicox's global commercialization strategy.

Braveheart Bio's stunning IPO debut raised nearly half a billion dollars. We dig into the story behind the numbers and what it signals for the 2026 economy.

NRx Pharmaceuticals announces a key FDA milestone for its ketamine therapy. This is a critical step, but the path to patient access is complex.

A landmark clinical trial for Progressive Supranuclear Palsy has begun. We deconstruct the novel platform design that offers new hope against a devastating disease.

For a rare brain disease with no cure, a revolutionary trial design offers a faster path to treatment and renewed hope for thousands of patients and families.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

A biotech firm has uncovered a self-perpetuating cycle that drives Alzheimer's from within the cell's mitochondria, and they've developed a drug to break it.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.